Form 4: Altimmune's Acting CFO, Andrew Shutterly, Reports Stock Purchase Through Employee Stock Purchase Plan

Andrew Shutterly, Acting CFO of Altimmune, Inc., reports the acquisition of 1,259 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.41 per share.

Summary

• On July 31, 2024, Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., acquired 1,259 shares of Altimmune's common stock.
• The purchase was made through Altimmune's 2019 Employee Stock Purchase Plan (ESPP).
• The shares were bought at a price of $5.41 per share, which represents 85% of the closing price of Altimmune's common stock on July 31, 2024.
• Following the reported transaction, Shutterly directly owns 11,372 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchase of shares by an officer suggests confidence, but it's a routine transaction through an established employee program.

Positives

• The purchase of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This particular filing reflects participation in an employee stock purchase plan, a common benefit offered by publicly traded companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals insider confidence.

Key Dates